Daiichi Sankyo | pharmaphorum

Wednesday 10 June 2026

Daiichi Sankyo

News

Datroway is first TROP2 drug for frontline breast cancer

Datroway is first TROP2 drug for frontline breast cancer

AZ and Daiichi's Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.

News

Daiichi Sankyo conference booth

Manufacturing hangover drives Daiichi Sankyo into the red

Long-term third-party manufacturing contracts and a slower-than-expected rollout of its cancer ADCs have driven Daiichi Sankyo into a net loss.

News

Daiichi Sankyo Lulu

Daiichi exits OTC, with $1.55bn unit sale to Suntory

Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.

News

Man on his smartphone while sitting on sifa

Daiichi teams up with GAIA for cholesterol DTx in Europe

Daiichi Sankyo has licensed European rights to GAIA's digital therapeutic for people with high cholesterol, currently in phase 3 testing.

Oncology

Daiichi Sankyo gears up for five ADC launches in 2026

Daiichi Sankyo gears up for five ADC launches in 2026

On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term strategy in ADCs.

News

John Tsai

Ex-Novartis CMO John Tsai joins Daiichi Sankyo

Daiichi Sankyo has named John Tsai as its new global head of R&D, replacing Ken Takeshita, who is stepping down after five years in the role.